Table 3.
Examples of Cur-Loaded Nanoformulations for Treatment of Different Diseases
| Disease | Cur-Loaded Nanoformulation | Animal | Major Outcome | References |
|---|---|---|---|---|
| Cancer | MPEG-PCL micelles | BALB/c mice | Sustained drug release Enhanced anti-cancer efficacy Improved anti-metastasis activity |
[51] |
| Brain injury | PLGA nanoparticles | Sprague Dawley rats | Down-regulated expression of NF-κB Decreased early brain injury induced by subarachnoid hemorrhage |
[168] |
| PLGA nanoparticles | Sprague Dawley rats | Improved neurological deficit Attenuated brain edema Enhanced therapeutic potential against subarachnoid hemorrhage- induced blood-brain barrier disruption |
[169] | |
| Wound healing | Dextran hydrogel incorporated PEG–PLA micelles | BALB/c mice | Acceptable biocompatibility Accelerated angiogenesis, fibroblast accumulation and wound healing |
[170] |
| PVA/Chitosan/ Curcumin patches |
Albino wistar rats | Increased bioavailability Improved anti-bacterial activity Enhanced wound healing |
[171] | |
| Malaria | PLGA nanoparticles | C57BL/6 mice | Enhanced and delayed uptake in the brain. Preventing degenerative changes in cerebral malaria |
[172] |
| PLGA nanoparticles | Swiss male albino mice | Higher potency against malaria parasite Higher safety |
[173] | |
| Asthma | Solid lipid nanoparticles |
BALB/c mice Sprague Dawley rats |
Enhanced bioavailability Increased tissue concentrations Suppressed airway hyperresponsiveness and inflammatory cell infiltration |
[174] |
| Psoriasis | Hydrogel coated PLGA nanoparticles | C57/BL6 mice | Enhanced topical penetration and system exposure Improved anti-psoriasis activity |
[175] |
| Arteriosclerosis | MPEG-PCL micelles | ApoE−/- mice | Inhibition of intraplaque neovascularization Reduced matrix metalloproteinases 2/9 activity and inflammatory response Regulation of lipoprotein cholesterol metabolism |
[176] |
| Leishmaniasis | Chitosan nanoparticles | Male albino rats | Satisfactory loading efficiency, stability and drug release characteristics Higher anti-leishmaniasis efficiency |
[177] |
| Bacterial infection | PVP nanoparticles | C57BL/6 mice | Improved anti-bacterial and anti-inflammatory effects Enhanced therapeutic potency of vancomycin |
[178] |